

EXPRESSION OF INTEREST APPLICATION FORM

SUBMISSION OF DOCUMENTS AND APPLICATION REVIEW PROCESS

Upon receipt, Kærtor Foundation will provide an email acknowledging receipt of application forms. Proposals will be competitively evaluated by a Scientific Committee including external advisors with expertise in drug discovery and others considered knowledgeable in the field. Assessment process will consist of the sum of the headings in the expression of interest. The font size should be 11 pt, and margins should be at least 2cm in all directions. Only a standard 'Arial' or 'other San Serif' font styles should be used.

A. Title of the research program

B. Applicant contact details

Name of principal researcher/Company representative*

Category*

Department*

Centre

University/Institution/Company*

Address*

Telephone *

Email address*

List of collaborators and/or other partners in the project. Identify supports and funding available for the project.*

Short CV of the principal investigator including the 5 more relevant achievements related to the project proposal.*
(Maximum extension: 1 page)

C. Proposed research program* (Maximum extension: 3 pages)

Pitch your Expression of Interest in 3 pages.

Provide a detailed description including:

a. Summary

- a1.** Therapeutic hypothesis.
- a2.** Details of the target or mechanism being targeted. Structural information (if available) and related pathways. Known modulators. Sites of action.

b. Rational/Evidences

Highlight the need and importance of the project, the degree of novelty, the risk and potential benefits.

c. Proposed research plan*

Short description of the research plan proposed, including milestones and timetable for each stage.

d. Current program status and expected clinical development approach

- d1.** Detail the current state of the project (mechanism of action, in vitro /in vivo studies, assay development, hits/leads/candidate).
- d2.** Indicate (if applicable) target population, existence of known biomarkers, clinical endpoints.

e. Program competitiveness

Existing drugs for this target or related targets
Existing treatment for the disease
Are there any on-going clinical trials involving this target/disease?

f. Intellectual property status

- f1.** Existing patents related with this research. On-going patents about this target-mechanism
- f2.** Is the proposed work related to an existing license, industry agreement or other relationship? If yes, please explain.

D. Primary areas of interest

Area	Subarea
Cardiovascular / Metabolism	
Immunology	
Infectious Diseases & Vaccines	
Neuroscience	
Oncology	
Transversal topics	
Other	Please specify

E. Secondary areas of interest

Area	Subarea
Cardiovascular / Metabolism	
Immunology	
Infectious Diseases & Vaccines	
Neuroscience	
Oncology	
Transversal topics	
Other	Please specify

F. Project type*

If you choose Other type, please specify:

For further information about the areas of interest please see the glossary:
<http://kaertorfoundation.org/en/glossary/>

The information contained in this glossary is explained in greater detail in the
[following presentation](#).

In addition, projects arising from clinical observations are also of great interest to Janssen. Some examples of such projects are included in the [following document](#) compiled by Johnson & Johnson.